SMLR - Earnings announcements

CAMPBELL, Calif., Oct. 28, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical devices and software to combat chronic diseases, today announced that due to its pending transaction with Strive, Inc., the company will not be hosting a conference call or providing an accompanying earnings presentation in conjunction with its third quarter 2025 financial results. Semler Scientific intends to file its Quarterly Report on Form 10-Q for the period ended September 30,

CAMPBELL, Calif., Aug. 4, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its Bitcoin holdings and other key performance indicators (KPIs). "We have made excellent progress with our Bitcoin treasury strategy," said Eric Semler, executive chairman of Semler Scientific. "We purchased approximately $195.4 million of Bitcoin s

CAMPBELL, Calif., May 13, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today reported financial results for the first quarter ended March 31, 2025 and provided an update on its bitcoin holdings and other key performance indicators (KPIs). "We continue to accretively grow our bitcoin arsenal using operating cash flow and proceeds from debt and equity financings," said Eric Semler, chairman of Semler Scientific. "And we a

SANTA CLARA, Calif., April 30, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a publicly traded company that has adopted bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of bitcoin, today announced updates regarding its bitcoin (BTC) activity, holdings and yield, its at-the-market equity offering (ATM) program and first quarter earnings release date and conference call. BTC Update Between April 25, 2025 and April 29, 2025, Semler Scientific acquired 165 bitcoins for $15.7 million with an average purchase price of $94,931 pe

SANTA CLARA, Calif., Feb. 18, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. "We are again pleased to report strong performance from our healthcare business with income from operations of $20.9 million for the full year 2024," said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. "While we continue to support innovation and growth

SANTA CLARA, Calif., Jan. 23, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced select preliminary unaudited fourth quarter 2024 financial results and BTC holdings. Semler Scientific will report full financial results for the fourth quarter and full year ended December 31, 2024, as well as provide an update on its Bitcoin holdings after the close of U.S. financial markets on Tuesday, February 18, 2025. Select Preliminary Unaudited

SANTA CLARA, Calif., Nov. 4, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the third quarter ended September 30, 2024. In addition, Semler Scientific announced the purchase of an additional 47 bitcoins for an aggregate amount of $3.0 million from operating cash flow since August 26, 2024. Semler Scientific now holds 1,058 bitcoins for a total purchase amount of $71.0 million as of November 4, 2024. "We are

SANTA CLARA, Calif., Oct. 21, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it will report financial results for the third quarter and nine months ended September 30, 2024, as well as provide an update on its Bitcoin holdings after the close of U.S. financial markets on Monday, November 4, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Eric Semler, chairman, Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating offi

SANTA CLARA, Calif., Aug. 5, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the second quarter ended June 30, 2024. In addition, the Company announced the purchase of an additional 101 bitcoins for an aggregate amount of $6.0 million. Since announcing the adoption of a bitcoin treasury strategy on May 28, 2024, the Company has purchased 929 bitcoins for a total of $63.0 million. "We are pleased to report st

SANTA CLARA, Calif., July 22, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it will report financial results for the second quarter and six months ended June 30, 2024, after the close of U.S. financial markets on Monday, August 5, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Eric Semler, chairman, Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating officer, will join him on the call. Please submit questions prio

2024 Q1 highlights compared to the corresponding period of 2023: First quarter revenues were $15.9 million, a decrease of 13%First quarter net income was $6.1 million, an increase of 22%Cash, cash equivalents and restricted cash balance increased to $62.9 millionSANTA CLARA, Calif., May 7, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the first quarter ended March 31, 2024. "We had

SANTA CLARA, Calif., April 23, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of U.S. financial markets on Tuesday, May 7, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating officer, will join him on the call.

2023 Q4 and full year highlights compared to the corresponding period of 2022: Fourth quarter revenues were $15.1 million, an increase of 9%Fourth quarter net income was $4.2 million, an increase of 31%Full year revenues were $68.2 million, an increase of 20%Full year net income was $20.6 million, an increase of 44%Cash balance increased to $57.3 millionSANTA CLARA, Calif., March 5, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.

SANTA CLARA, Calif., Feb. 21, 2024 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023, after the close of U.S. financial markets on Tuesday, March 5, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating officer, will join him on the call.

2023 Q2 highlights: Revenue was $18.6 million, an increase of 25% compared to the corresponding period of 2022Net income was $5.9 million, an increase of 44% compared to the corresponding period of 2022Cash, cash equivalents and short-term investments of $51.8 millionSANTA CLARA, Calif., Aug. 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three and six months ended June 30, 2023.

SANTA CLARA, Calif., July 28, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of U.S. financial markets on Thursday, August 10, 2023. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormier, chief financial officer, will join him on the call.

2023 Q1 highlights: Revenue was $18.2 million, an increase of 30% compared to the corresponding period of 2022Net income was $5.0 million, an increase of 48% compared to the corresponding period of 2022Cash, cash equivalents and short-term investments of $43.0 millionSANTA CLARA, Calif., May 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the three months ended March 31, 2023. "W

SANTA CLARA, Calif., May 1, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the first quarter ended March 31, 2023, after the close of U.S. financial markets on Wednesday, May 10, 2023. Doug Murphy-Chutorian, M.D., interim chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior vice president, finance and accounting, Dennis Rosenberg, chief marketing officer, and Renae Cormier, head of corporate communications and business strategy,

2022 Q4 and Full Year highlights compared to the corresponding period of 2021: Fourth quarter revenue was $13.8 million, an increase of 20%Fourth quarter net income was $3.2 million, an increase of 113%Full year revenue was $56.7 million, an increase of 7%Full year net income was $14.3 million, a decrease of 17%Cash at December 31, 2022 increased to $43.1 million, including short-term investmentsCorporate update: CEO transition announced; see separate press release issued todaySANTA CLARA, Calif., March 21, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, toda

SANTA CLARA, Calif., March 10, 2023 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, after the close of U.S. financial markets on Tuesday, March 21, 2023. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior vice president, finance and accounting, Dennis Rosenberg, chief marketing officer, and Renae Cormier, head of corporate communications and busin

2022 Q3 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenue was $14.0 million, same as the prior year periodNet income was $3.7 million, or $0.55 per basic share and $0.46 per diluted share, compared to $4.2 million, or $0.61 per basic share and $0.51 per diluted shareCash and cash equivalents at September 30, 2022 increased to $45.5 million from $35.9 millionSANTA CLARA, Calif., Nov. 1, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and nine months ended September 30, 2022. "We achieved a

SANTA CLARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the third quarter and first nine months ended September 30, 2022, after the close of U.S. financial markets on Tuesday, November 1, 2022. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior vice president, finance and accounting, Dennis Rosenberg, chief marketing officer, and Renae Cormier, head of corporate communications

2022 Q2 quarterly HIGHLIGHTS compared to the corresponding period of 2021: Revenues were $14.8 million, an increase of 4%, compared to $14.3 millionNet income was $4.1 million, or $0.60 per basic share and $0.51 per diluted share, compared to $6.7 million, or $1.00 per basic share and $0.83 per diluted shareCash and cash equivalents at June 30, 2022 increased to $40.0 million from $28.5 millionSANTA CLARA, Calif., Aug. 2, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and six months ended June 30, 2022. "We achi

SANTA CLARA, Calif., July 21, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the second quarter and first half ended June 30, 2022, after the close of U.S. financial markets on Tuesday, August 2, 2022. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Andrew Weinstein, senior vice president, finance and accounting, Dennis Rosenberg, chief marketing officer, and Renae Cormier, head of corporate communications and business

2022 Q1 HIGHLIGHTS compared to the corresponding period of 2021: Revenues were $14.0 million, an increase of $0.8 million, or 6%, compared to $13.2 millionNet income was $3.4 million, or $0.50 per basic share and $0.41 per diluted share, compared to $4.9 million, or $0.73 per basic share and $0.60 per diluted shareCash at March 31, 2022 increased to $38.4 million from $26.5 millionSANTA CLARA, Calif., May 2, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three months ended March 31, 2022. "Our goal is for QuantaFlo® t

SANTA CLARA, Calif., April 19, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the first quarter ended March 31, 2022, after the close of U.S. financial markets on Monday, May 2, 2022. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.  Andrew Weinstein, senior vice president, finance and accounting, and Dennis Rosenberg, chief marketing officer, will join him on the call. We encourage participants to pre-register for the c

SANTA CLARA, Calif., Feb. 28, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three months and year ended December 31, 2021. "It is our belief that annual adoption of our QuantaFlo® product continues to expand due to the clinical benefits of earlier recognition of vascular disease," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "In 2021 as compared to 2020, we experienced a timing shift in the home-testing market (fee-per-test), which led to first half revenue being greater than the s

SANTA CLARA, Calif., Feb. 17, 2022 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021, after the close of U.S. financial markets on Monday, February 28, 2022. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.  Andrew Weinstein, senior vice president, finance and accounting, and Dennis Rosenberg, chief marketing officer, will join him on the call. We encourage participants to

SANTA CLARA, Calif., Nov. 1, 2021 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today reported financial results for the three and nine months ended September 30, 2021. "Revenues and earnings continued to be strong compared to last year," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. "We did experience a sequential decline in fee-per-test revenue for the third quarter compared to the second quarter. We believe this change may be due in part to the Delta variant and to some level of seasonality." FINANCIAL RESULTS For the quarter

SANTA CLARA, Calif., Oct. 22, 2021 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for the third quarter and first nine months ended September 30, 2021, after the close of U.S. financial markets on Monday, November 1, 2021. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day.  Andrew Weinstein, senior vice president, finance and accounting, and Dennis Rosenberg, chief marketing officer, will join him on the call. We encourage particip